{'fraction_non_alphanumeric': 0.01002004008016032, 'fraction_numerical': 0.0, 'mean_word_length': 5.889655172413793, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Radionuclide monitoring of left ventricular function

ConclusionsSeveral devices have been evaluated and validated for continuous monitoring of LV function. The diagnostic and prognostic roles of these techniques appear to be predominant in patients with CAD. Silent myocardial ischemia may be widely evaluated by these systems, which allow the clinician to predict ischemic cardiac events, perform risk stratification, and guide treatment in patients with CAD more accurately than can be done with exercise test results. In fact, it has been demonstrated that adverse cardiac events are more commonly observed during routine daily activities.The continuous improvement in miniaturizing these devices and the capability of online processing of data could make this technique useful and widely acceptable, facilitating simultaneous assessment of hemodynamic and metabolic changes in silent LV dysfunction and continuing to play an important role in noninvasive evaluation of ventricular performance.